2. Academic Validation
  3. A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution

  • Cell Rep. 2017 Jul 25;20(4):999-1015. doi: 10.1016/j.celrep.2017.07.006.
Grace R Anderson 1,  Peter S Winter 2,  Kevin H Lin 1,  Daniel P Nussbaum 3,  Merve Cakir 1,  Elizabeth M Stein 1,  Ryan S Soderquist 1,  Lorin Crawford 4,  Jim C Leeds 1,  Rachel Newcomb 1,  Priya Stepp 1,  Catherine Yip 1,  Suzanne E Wardell 1,  Jennifer P Tingley 1,  Moiez Ali 1,  Mengmeng Xu 1,  Meagan Ryan 5,  Shannon J McCall 6,  Autumn J McRee 7,  Christopher M Counter 1,  Channing J Der 5,  Kris C Wood 8
Affiliations

Affiliations

  • 1 Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27710, USA.
  • 2 Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27710, USA; Program in Genetics and Genomics, Duke University, Durham, NC 27710, USA.
  • 3 Department of Surgery, Duke University, Durham, NC 27710, USA.
  • 4 Department of Statistics, Duke University, Durham, NC 27710, USA.
  • 5 Department of Pharmacology, University of North Carolina, Chapel Hill, NC 27599, USA.
  • 6 Department of Pathology, Duke University, Durham, NC 27710, USA.
  • 7 Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.
  • 8 Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27710, USA. Electronic address: kris.wood@duke.edu.
PMID: 28746882 DOI: 10.1016/j.celrep.2017.07.006
Abstract

Combinatorial inhibition of effector and feedback pathways is a promising treatment strategy for KRAS mutant cancers. However, the particular pathways that should be targeted to optimize therapeutic responses are unclear. Using CRISPR/Cas9, we systematically mapped the pathways whose inhibition cooperates with drugs targeting the KRAS effectors MEK, ERK, and PI3K. By performing 70 screens in models of KRAS mutant colorectal, lung, ovarian, and pancreas cancers, we uncovered universal and tissue-specific sensitizing combinations involving inhibitors of cell cycle, metabolism, growth signaling, chromatin regulation, and transcription. Furthermore, these screens revealed secondary genetic modifiers of sensitivity, yielding a Src inhibitor-based combination therapy for KRAS/PIK3CA double-mutant colorectal cancers (CRCs) with clinical potential. Surprisingly, acquired resistance to combinations of growth signaling pathway inhibitors develops rapidly following treatment, but by targeting signaling feedback or apoptotic priming, it is possible to construct three-drug combinations that greatly delay its emergence.

Keywords

BIM; CRISPR/Cas9; KRAS; PIK3CA; SRC; apoptosis; drug resistance; pooled screening; synthetic lethality.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z